Currently Available Treatment Options for Patients With Myelofibrosis

Opinion
Video

Abdulraheem Yacoub, MD, reviews the current myelofibrosis treatment landscape including the four approved JAK inhibitors - ruxolitinib, fedratinib, pacritinib, and momelotinib - discussing the clinical trial data and indications for each in first-line and second-line settings.

Recent Videos
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Guillermo Garcia-Manero, MD, an expert on MDS
Guillermo Garcia-Manero, MD, an expert on MDS
Guillermo Garcia-Manero, MD, an expert on MDS
Guillermo Garcia-Manero, MD, an expert on MDS
Guillermo Garcia-Manero, MD, an expert on MDS
Related Content